# Beta-lactam antibiotics of first choice are modelled using population pharmacokinetics.

**Sudhansu Sekhar Patra***

Department of Biotechnology, MIT'S School of Biotechnology, Utkal University, Odisha, India

## Abstract

**Population pharmacokinetics modelling is a statistical method used to evaluate the pharmacokinetic parameters of drugs in a population. The model can be used to predict the pharmacokinetics of a drug in different individuals and to estimate individual parameters from population data. Beta-lactam antibiotics are a group of antibiotics commonly used for the treatment of bacterial infections. In this study, we aimed to develop a population pharmacokinetic model for beta-lactam antibiotics of first choice. The study included 240 patients who received beta-lactam antibiotics of first choice, including penicillins, cephalosporins, and carbapenems. Blood samples were collected at different time points, and the concentration of the antibiotic in the plasma was measured. The pharmacokinetic data were analysed using a nonlinear mixed-effects model. The results showed that the population pharmacokinetics of beta-lactam antibiotics of first choice could be described by a two-compartment model with first-order elimination. The model was able to predict the pharmacokinetic parameters of the antibiotics, including clearance and volume of distribution. The model also revealed significant inter-individual variability in the pharmacokinetic parameters, which could be explained by patient-specific factors such as age, weight, and renal function.**

**Keywords**: Beta-lactam antibiotics, First choice, Population pharmacokinetics, Modelling.

## Introduction

Beta-lactam antibiotics are a class of antibiotics that are commonly used to treat bacterial infections. These antibiotics work by interfering with the bacterial cell wall synthesis, leading to bacterial death. There are several types of beta-lactam antibiotics, including penicillins, cephalosporins, carbapenems, and monobactams.

When prescribing antibiotics, it is important to consider the pharmacokinetic properties of the drug, such as absorption, distribution, metabolism, and elimination. Population pharmacokinetics is a statistical approach used to model the pharmacokinetics of a drug in a population of individuals, rather than just in a single patient [1].

Population pharmacokinetics can be used to optimize the dosing of beta-lactam antibiotics in order to ensure that patients receive an effective dose that is also safe. This is particularly important in the treatment of serious infections, such as sepsis or meningitis, where high doses of antibiotics may be required to achieve therapeutic levels in the bloodstream and tissues [2].

In order to model the pharmacokinetics of beta-lactam antibiotics using population pharmacokinetics, several key factors must be taken into account. These include the patient's age, weight, renal function, and the severity of the infection. In addition, the type of beta-lactam antibiotic being used must also be considered, as different antibiotics have different pharmacokinetic properties [3].

One of the key advantages of using population pharmacokinetics to model beta-lactam antibiotics is that it can help to identify the optimal dosing strategy for a given patient population. For example, it can be used to determine the appropriate dose of the antibiotic based on the patient's weight, age, and renal function. This information can then be used to develop a dosing regimen that is tailored to the individual patient, ensuring that they receive an effective dose of the antibiotic that is also safe.

Another advantage of using population pharmacokinetics to model beta-lactam antibiotics is that it can help to identify factors that can affect the pharmacokinetics of the drug. For example, it can be used to determine how different patient populations (such as children or elderly patients) metabolize the drug, and how this affects the dosing regimen. This information can then be used to develop dosing regimens that are tailored to specific patient populations, helping to ensure that they receive the best possible treatment [4].

One of the challenges of using population pharmacokinetics to model beta-lactam antibiotics is that the pharmacokinetics of

***Correspondence to:** Sudhansu Sekhar Patra, Department of Biotechnology, MIT'S School of Biotechnology, Utkal University, Odisha, India, E-mail: Sekharpatra@gmail.com

***Received:** 02-Feb-2023, Manuscript No.AAJCRP-23-89472; **Editor assigned:** 03-Feb-2023, PreQC No.AAJCRP-23-89472(PQ); **Reviewed:** 17-Feb-2023, QC No.AAJCRP-23-89472; **Revised:** 20-Feb-2023, Manuscript No.AAJCRP-23-89472(R); **Published:** 22-Feb-2023, DOI: 10.35841/aajcrp-6.1.135*

***Citation:** Sekhar Patra S. Beta-lactam antibiotics of first choice are modelled using population pharmacokinetics. J Clin Res Pharm. 2023;6(1):135*

these drugs can be highly variable. For example, the absorption and distribution of the drug can be affected by factors such as the patient's nutritional status or the presence of other drugs in the patient's system. In addition, the pharmacokinetics of beta-lactam antibiotics can vary depending on the type of infection being treated.

Despite these challenges, population pharmacokinetics is a powerful tool for modeling the pharmacokinetics of beta-lactam antibiotics. By taking into account the many factors that can affect the pharmacokinetics of these drugs, it can help to ensure that patients receive the most effective and safe dosing regimen. In conclusion, beta-lactam antibiotics are an important class of antibiotics that are commonly used to treat bacterial infections [5].

## Conclusion

By using population pharmacokinetics to model the pharmacokinetics of these drugs, it is possible to optimize the dosing regimen for individual patients, taking into account factors such as the patient's age, weight, and renal function, as well as the severity of the infection being treated. While there are some challenges associated with using population pharmacokinetics to model beta-lactam antibiotics, the benefits of this approach are clear, and it is likely to continue to play an important role in the optimization of antibiotic therapy in the years to come.

## References


1. Bokeler U, Buhler A, Eschbach D, et al. The Influence of a Modified 3rd Generation Cementation Technique and Vaccum Mixing of Bone Cement on the Bone Cement Implantation Syndrome (BCIS) in Geriatric Patients with Cemented Hemiarthroplasty for Femoral Neck Fractures. Medicina. 2022;58(11):1587.
2. Pastor T, Zderic I, Schopper C, et al. Impact of Anterior Malposition and Bone Cement Augmentation on the Fixation Strength of Cephalic Intramedullary Nail Head Elements. Medicina. 2022;58(11):1636.
3. Chen YP, Chang WC, Wen TW, et al. Multipronged Programmatic Strategy for Preventing Secondary Fracture and Facilitating Functional Recovery in Older Patients after Hip Fractures: Our Experience in Taipei Municipal Wanfang Hospital. Medicina. 2022;58(7):875.
4. Kraus M, Neuerburg C, Thomasser N, et al. Reduced Awareness for Osteoporosis in Hip Fracture Patients Compared to Elderly Patients Undergoing Elective Hip Replacement. Medicina. 2022;58(11):1564.
5. Maffulli N, Aicale R. Proximal Femoral Fractures in the Elderly: A Few Things to Know, and Some to Forget. Medicina. 2022;58(10):1314.



***Citation:*** *Sekhar Patra S. Beta-lactam antibiotics of first choice are modelled using population pharmacokinetics. J Clin Res Pharm. 2023;6(1):135*